ClinicalTrials.gg
CompletedNCT03449446ATLASUpdated Dec 3, 2020Results posted

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of SEL and FIR in Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Completed at 101 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-03.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
4th of 16
395 · median 161
Started
2018
with 1 other
Phase 2
11 of 16
none open now
Registered
13th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 13th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

The primary objectives of this study are:

  • To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in combination, in participants with bridging fibrosis or compensated cirrhosis due to NASH
  • To evaluate changes in liver fibrosis, without worsening of NASH
03

Conditions studied

  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Liver consistent with NASH and F3 or F4 in the opinion of the central reader
  • In participants who have never had a liver biopsy, liver stiffness by FibroScan® ≥ 14.0 kPa and Enhanced Liver Fibrosis (ELF™) Test score ≥ 9.8 at Screening
  • Screening laboratory parameters, as determined by the central laboratory:

    • Estimated (eGFR) ≥ 60 mL/min, as calculated by the equation
    • (HbA1c) ≤ 9.5%
    • (ALT) \< 5 x (ULN)
    • count ≥ 125,000/μL

Key Exclusion Criteria:

  • Prior history of decompensated liver disease including ascites, hepatic encephalopathy, or variceal bleeding
  • (CP) score > 6 at Screening, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation
  • Model for End-Stage Liver Disease (MELD) score > 12 at Screening, unless due to an alternate etiology such as therapeutic anticoagulation
  • Other causes of liver disease based on medical history and/or centralized review of liver histology, including but not limited to: alcoholic liver disease, , , disorders (eg, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, iron overload, or alpha-1-antitrypsin deficiency requiring treatment
  • History of liver transplantation
  • Current or prior history of hepatocellular carcinoma

Note: Other protocol defined Inclusion/ Exclusion criteria may apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    Selonsertib (SEL)

    Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.

    Drug: SEL · Drug: Placebo to match FIR · Drug: Placebo to match CILO

  • Experimental
    Firsocostat (FIR)

    Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.

    Drug: FIR · Drug: Placebo to match CILO · Drug: Placebo to match SEL

  • Experimental
    Cilofexor (CILO)

    Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.

    Drug: CILO · Drug: Placebo to match FIR · Drug: Placebo to match SEL

  • Experimental
    Selonsertib (SEL) + Firsocostat (FIR)

    Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.

    Drug: SEL · Drug: FIR · Drug: Placebo to match CILO

  • Experimental
    Selonsertib (SEL) + Cilofexor (CILO)

    Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.

    Drug: SEL · Drug: CILO · Drug: Placebo to match FIR

  • Experimental
    Firsocostat (FIR) + Cilofexor (CILO)

    Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.

    Drug: FIR · Drug: CILO · Drug: Placebo to match SEL

  • Experimental
    Placebo

    Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.

    Drug: Placebo to match FIR · Drug: Placebo to match CILO · Drug: Placebo to match SEL

Interventions

  • DrugSEL

    18 mg tablet administered orally once daily without regard to food

  • DrugFIR

    20 mg tablet administered orally once daily without regard to food

    Also known as: GS-0976

  • DrugCILO

    30 mg tablet administered orally once daily without regard to food

    Also known as: GS-9674

  • DrugPlacebo to match FIR

    Tablet administered orally once daily without regard to food

  • DrugPlacebo to match CILO

    Tablet administered orally once daily without regard to food

  • DrugPlacebo to match SEL

    Tablet administered orally once daily without regard to food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 48 weeks plus 30 days

  2. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.

    Time frame: First dose date up to 48 weeks plus 30 days

  3. Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48

    Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network classification (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. The 95% CI was based on the Clopper-Pearson method.

    Time frame: Week 48

07

Results

Posted Dec 3, 2020

Participant flow

Participants were enrolled at study sites in United States, Australia, Canada, Hong King and New Zealand. The first participant was screened on 21 Mar 2018. The last study visit occurred on 19 Nov 2019.

Participant flow — Overall Study
MilestoneSelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlacebo
Started39404180787839
Completed3333471666938
Not completed367791291
Withdrew: Randomized but never treated0011100
Withdrew: Unknown reason33111220
Withdrew: Withdrew consent1314441
Withdrew: Adverse event1210020
Withdrew: Lost to follow-up0021300
Withdrew: Investigator's discretion0112000
Withdrew: Non compliance with study drug1000000
Withdrew: Protocol violation0000110
Withdrew: Death0000100

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Time frame:
First dose date up to 48 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsSelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlacebo
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)84.685.092.588.696.191.079.5
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. Participants with any laboratory abnormality were reported.

Time frame:
First dose date up to 48 weeks plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
percentage of participantsSelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlacebo
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities94.9100.097.598.796.1100.094.9
PrimaryPercentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48

Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network classification (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. The 95% CI was based on the Clopper-Pearson method.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 48
percentage of participantsSelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlacebo
Percentage of Participants Who Achieved a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 4828.6 (3.7 to 71.0)12.1 (3.4 to 28.2)11.8 (3.3 to 27.5)15.5 (8.0 to 26.0)19.1 (10.6 to 30.5)20.9 (11.9 to 32.6)10.5 (2.9 to 24.8)
Statistical analysis
  • Firsocostat vs Placebo · Mantel Haenszel · p = 0.9449 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted Mantel-Haenszel (MH) method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 0.6 · 95% CI -17.6 to 18.8The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • Cilofexor vs Placebo · Mantel Haenszel · p = 0.9646 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 0.4 · 95% CI -17.6 to 18.4The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • SEL + FIR vs Placebo · Mantel Haenszel · p = 0.6219 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 3.7 · 95% CI -10.9 to 18.3The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • SEL + CILO vs Placebo · Mantel Haenszel · p = 0.2554 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 8.8 · 95% CI -6.4 to 24.1The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • FIR + CILO vs Placebo · Mantel Haenszel · p = 0.1658 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 10.8 · 95% CI -4.5 to 26.1The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • Firsocostat vs SEL + FIR · Mantel Haenszel · p = 0.6963 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 3.2 · 95% CI -12.9 to 19.4The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • Firsocostat vs FIR + CILO · Mantel Haenszel · p = 0.2441 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 10.0 · 95% CI -6.8 to 26.8The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • Cilofexor vs SEL + CILO · Mantel Haenszel · p = 0.5229 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 5.2 · 95% CI -10.7 to 21.0The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.
  • Cilofexor vs FIR + CILO · Mantel Haenszel · p = 0.2149 (The p-value between each pair of treatment groups presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.) · Difference in percentages: 10.4 · 95% CI -6.0 to 26.9The percentage difference and 95% C.I. presented were obtained by the stratum-adjusted MH method, with baseline diabetes mellitus status and baseline cirrhosis status as stratification factors.

Adverse events

Collected over First dose date up to 48 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selonsertib0/39 (0%)7/39 (17.9%)30/39 (76.9%)
Firsocostat0/40 (0%)3/40 (7.5%)30/40 (75%)
Cilofexor0/40 (0%)8/40 (20%)34/40 (85%)
SEL + FIR0/79 (0%)7/79 (8.9%)67/79 (84.8%)
SEL + CILO1/77 (1.3%)10/77 (13%)68/77 (88.3%)
FIR + CILO0/78 (0%)8/78 (10.3%)66/78 (84.6%)
Placebo0/39 (0%)2/39 (5.1%)29/39 (74.4%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventSelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlacebo
CellulitisInfections and infestations0/390/403/401/790/770/780/39
Abdominal painGastrointestinal disorders1/390/400/400/790/770/780/39
Abdominal pain lowerGastrointestinal disorders1/390/400/400/790/770/780/39
ConstipationGastrointestinal disorders1/390/400/400/790/770/780/39
DysphagiaGastrointestinal disorders1/390/400/400/790/770/780/39
Gastric ulcer haemorrhageGastrointestinal disorders0/390/400/400/790/770/781/39
Umbilical herniaGastrointestinal disorders1/390/400/400/790/770/780/39
Colonic abscessInfections and infestations1/390/400/400/790/770/780/39
Kidney infectionInfections and infestations0/390/400/400/790/770/781/39
Meniscus injuryInjury, poisoning and procedural complications1/390/400/400/790/770/780/39
Most frequent other events
Showing 10 of 60
Most frequent other events
EventSelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlacebo
PruritusSkin and subcutaneous tissue disorders7/395/408/4012/7920/7719/785/39
NauseaGastrointestinal disorders3/396/403/4020/7910/7710/781/39
Upper respiratory tract infectionInfections and infestations4/397/404/4014/7912/778/789/39
HeadacheNervous system disorders4/397/404/4011/796/7715/783/39
Abdominal painGastrointestinal disorders7/392/403/406/796/777/782/39
FatigueGeneral disorders5/397/403/4014/799/778/783/39
DiarrhoeaGastrointestinal disorders2/395/400/4011/797/7713/782/39
Urinary tract infectionInfections and infestations6/393/405/409/799/776/782/39
NasopharyngitisInfections and infestations2/394/406/403/793/779/785/39
ConstipationGastrointestinal disorders2/390/404/408/7911/776/783/39

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
Mean59 ± 10.460 ± 10.057 ± 10.259 ± 8.360 ± 9.061 ± 8.461 ± 8.260 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
Female24252949514827253
Male15151130263012139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
Race — American Indian or Alaska Native10011104
Race — Asian730345325
Race — Black01012217
Race — Native Hawaiian or Pacific Islander01000001
Race — White30354073686835349
Race — Not Permitted10000001
Race — Other00012205
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
Ethinicity — Hispanic or Latino891418251714105
Ethinicity — Not Hispanic or Latino31312660526025285
Ethinicity — Not Permitted00010102
Region of Enrollment
Region of Enrollment(participants)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
New Zealand10000001
Canada322543322
Hong Kong200322110
United States30353767666635336
Australia331457023
Diabetes Mellitus Status
Diabetes Mellitus Status(Participants)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
Present26302757585727282
Absent13101322192112110
Cirrhosis Status
Cirrhosis Status(Participants)SelonsertibFirsocostatCilofexorSEL + FIRSEL + CILOFIR + CILOPlaceboTotal
Cirrhotic21222246464222221
Non-Cirrhotic18181833313617171
08

Study locations

101 sites
  • The Institute for Liver Health
    Chandler, Arizona 85224-5688, United States
  • Mayo Clinic Arizona, Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Liver Wellness Center
    Little Rock, Arkansas 72204, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • eStudySite
    Chula Vista, California 91911-6660, United States
  • Southern California Liver Center
    Coronado, California 92118, United States
  • Fresno Clinical Research Center
    Fresno, California 93720, United States
  • UCSD NAFLD Clinical Research Center
    La Jolla, California 92037, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 99352, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • Huntington Medical Research Institutes Liver Center
    Pasadena, California 91105, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • University of California, Davis Medical Center (study visits)
    Sacramento, California 95817, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • South Denver Gastroenterology, PC
    Englewood, Colorado 80113, United States
  • Integrity Clinical Research
    Doral, Florida 33166, United States
  • UF Hepatology Research at CTRB
    Gainesville, Florida 32610, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • IMIC Inc
    Miami, Florida 33157, United States
  • Genoma Research Group
    Miami, Florida 33165, United States
  • Florida Research Institute
    Tampa, Florida 34211, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Piedmont Hospital
    Atlanta, Georgia 30309, United States
  • Gastrointestinal Diseases Research
    Columbus, Georgia 31904, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Northwestern University; Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Indianapolis Gastroenterology Research Foundation
    Indianapolis, Indiana 46237, United States
  • Iowa Digestive Disease Center, P.C.
    Clive, Iowa 50325, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Delta Research Partners, LLC
    Bastrop, Louisiana 71220, United States
  • Tulane University
    New Orleans, Louisiana 70112, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health Systems
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Southern Therapy and Advanced Research (STAR) LLC
    Ridgeland, Mississippi 39157, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Saint Louis University
    Saint Louis, Missouri 63110, United States
  • Jubilee Clinical Research, Inc.
    Las Vegas, Nevada 89106, United States
  • Rutgers New Jersey Medical School- Doctors Office Center
    Newark, New Jersey 07103, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Sandra Atlas Bass Center for Liver Diseases and Transplantation
    Manhasset, New York 11030, United States
  • Icahn School of Medicine at Mount Sinai Beth Israel
    New York, New York 10003, United States
  • Concorde Medical Group, PLLC
    New York, New York 10016, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Carolinas Healthcare System Center for Liver Disease and Transplant
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center, Duke South Clinics
    Durham, North Carolina 27710, United States
  • Cumberland Research Associates, LLC
    Fayetteville, North Carolina 28304, United States
  • Consultants for Clinical Research wed
    Cincinnati, Ohio 45249, United States
  • Hospital of the University of Pennsylvania- Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC - Center for Liver Diseases at the Thomas E. Starlz Institute
    Pittsburgh, Pennsylvania 15213, United States
  • VA Pittsburgh Healthcare System
    Pittsburgh, Pennsylvania 15240, United States
  • University Gastroenterology
    Providence, Rhode Island 02905, United States
  • Medical University of South Carolina (Liver Biopsy)
    Charleston, South Carolina 29425, United States
  • GHS Gastroenterology and Liver Center
    Greenville, South Carolina 29605, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Quality Medical Research, PLLC
    Nashville, Tennessee 37211, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • Pinnacle Clinical Research, PLLC
    Austin, Texas 78746, United States
  • Austin Center for Clinical Research
    Austin, Texas 78758, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • University of Texas Southwestern Medical Center Internal Medicine Digestive and Liver Diseases Clinical Trials
    Dallas, Texas 75390, United States
  • Baylor College of Medicine - Advanced Liver Therapies
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Pinnacle Clinical Research
    Live Oak, Texas 78233, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Intermountain Liver Disease and Transplant Center
    Murray, Utah 84107, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • University of Virginia Medical Center
    Charlottesville, Virginia 22908, United States
  • California Pacific Medical Center - Sutter Pacific Medical Foundation San Francisco Center for Liver Disease Dept. of Transplant
    Falls Church, Virginia 22042, United States
  • Digestive and Liver Disease Specialists
    Norfolk, Virginia 23502, United States
  • Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Swedish Organ Transplant and Liver Center
    Seattle, Washington 98104, United States
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Monash Health, Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Melbourne Health, Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • St Vincent's Hospital Sydney
    Darlinghurst, 2010, Australia
  • Austin Health
    Heidelberg, 3084, Australia
  • The Alfred Hospital, Alfred Health
    Melbourne, 3004, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • William Osler Health System-Brampton Civic Hospital
    Brampton, L6R 3J7, Canada
  • University of Calgary Liver Unit (Heritage Medical Research Clinic)
    Calgary, T2N 4Z6, Canada
  • Chronic Viral Illness Service McGill University Health Centre (MUHC)/ Royal Victoria Hospital
    Montreal, H4A 3J1, Canada
  • Toronto General Hospital
    Toronto, M5G 2C4, Canada
  • Toronto Liver Centre
    Toronto, M6H 3M1, Canada
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Auckland City Hospital
    Auckland, 1023, New Zealand

Showing the first 100 of 101 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Loomba R, et al. Safety and efficacy of combination therapies including cilofexor/firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the Phase 2b ATLAS trial [accepted for oral presentation]. European Association for the Study of the Liver (EASL); 2020; Virtual.
  • Loomba R, Alkhouri N, Strasser S, Wong VWS, Schall RA, McColgan B, et al. Clinical utility and application of non-invasive tests of fibrosis in the selection of patients with advanced fibrosis due to NASH in the Phase 2 ATLAS trial (Poster SAT-315). EASL; 2019; Vienna, Austria.
  • Loomba R, Alkhouri N, Patel K, Zhang J, McColgan BJ, Djedjos S, et al. Validation of Cutoffs for Controlled Attenuation Parameter with MRI-Proton Density Fat Fraction (PDFF) as a Reference Standard in Subjects with Nonalcoholic Steatohepatitis (NASH) Across Multiple Randomized, Controlled Trials (Poster 1727). American Association for the Study of Liver Diseases (AASLD); 2019; Boston, MA, USA.
  • Loomba R, Alkhouri N, Noureddin M, Zhang J, McColgan BJ, Djedjos S, et al. Validation of the Diagnostic Accuracy of Magnetic Resonance Elastography (MRE) for the Detection of Advanced Fibrosis Due to Nash Across Multiple Phase 2 and 3 Clinical Trials (Poster 1728). AASLD; 2019; Boston, MA, USA.
  • Alkhouri N, Strasser SI, Wong VWS, Aguilar R, Chuang J, Huss R, et al. Alcohol use is Underreported in Clinical Trials of NASH: Baseline Alcohol Biomarkers from a Phase 2 Clinical Trial (Poster 1765). AASLD; 2019; Boston, MA, USA.
  • Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; for the ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology. 2021 Feb;73(2):625-643. doi: 10.1002/hep.31622. PubMed 33169409 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2019, 19 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 19 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2018
First posted
Feb 28, 2018
StartActual
Mar 21, 2018
Primary completionActual
Oct 30, 2019
CompletionActual
Nov 19, 2019
Results first posted
Dec 3, 2020
Last update
Dec 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03449446
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Mar 21, 2018
Primary completion
Oct 30, 2019
Completion
Nov 19, 2019
Results posted
Dec 3, 2020
Last update
Dec 3, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selonsertib · Firsocostat · Cilofexor

Start the discussion